6-Oxo-6-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino]hexanoic acid | 138080-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-Oxo-6-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino]hexanoic acid
• CAS: 138080-12-3
• 化学式: C₈H₁₂N₄O₅S₂
• 分子量: 308.339
• InChiKey: MEEQHWQTWYNUGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  189
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(allyloxy)-4-oxobutanoic acid 、 5-[[芴甲氧羰基]氨基]戊酸 、 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸三叔丁酯 、 N-芴甲氧羰基-1,3-丙二胺盐酸盐 、 6-Oxo-6-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino]hexanoic acid 在 N,N-二异丙基乙胺 、 哌啶 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3S)-4-oxo-3-[5-[[6-oxo-6-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino]hexanoyl]amino]pentanoylamino]-4-[4-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]butylamino]butanoic acid
  参考文献：
  名称：

  碳酸酐酶IX靶向放射性诊疗药物及其制备方法

  摘要：

  本发明涉及碳酸酐酶IX靶向放射性诊疗药物及其制备方法，具体地，本发明涉及一种化合物或其药学上可接受的盐、酯或溶剂化物，其结构如式(I)所示，所述化合物能用于诊断和/或治疗一种或多种表达碳酸酐酶IX的肿瘤、癌症或细胞#imgabs0#

  公开号：

  CN117186087A
• 作为产物：
  描述：

  甲基脂肪酰氯 在 4-二甲氨基吡啶 、 sodium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 6-Oxo-6-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino]hexanoic acid
  参考文献：
  名称：

  Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity

  摘要：

  New carbonic anhydrase (EC 4.2.1.1) inhibitors were synthesized as potential drugs for the topical treatment of glaucoma. They were obtained by substituting the acetyl group of acetazolamide and methazolamide with bicarboxylic acids of different chain length (C4-C6). The terminal carboxyl was either kept free or esterified with alcohols of different size (C1-C12). A gamma-aminovaleric derivative was also prepared. All compounds proved active as carbonic anhydrase inhibitors in vitro, with an average IC50 of about 0.5-mu-M. Some proved also to be topically active in vivo in lowering the artificially elevated intraocular pressure in rabbits. The most active compound, carrying a succinic acid side chain, is the most soluble in aqueous buffers. Its duration of action is about 8 h and it is under evaluation as a topical antiglaucoma drug. It is hypothesized that the duration of action could be longer in compounds having both the same high water solubility and partition coefficient.

  DOI：

  10.1021/jm00092a021

文献信息

• Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity
  作者：Simonetta Antonaroli、Armandodoriano Bianco、Mario Brufani、Luciano Cellai、Giuseppe Lo Baido、Edoardo Potier、Luciano Bonomi、Sergio Perfetti、Anna Ida Fiaschi、Giorgio Segre

  DOI：10.1021/jm00092a021

  日期：1992.7

  New carbonic anhydrase (EC 4.2.1.1) inhibitors were synthesized as potential drugs for the topical treatment of glaucoma. They were obtained by substituting the acetyl group of acetazolamide and methazolamide with bicarboxylic acids of different chain length (C4-C6). The terminal carboxyl was either kept free or esterified with alcohols of different size (C1-C12). A gamma-aminovaleric derivative was also prepared. All compounds proved active as carbonic anhydrase inhibitors in vitro, with an average IC50 of about 0.5-mu-M. Some proved also to be topically active in vivo in lowering the artificially elevated intraocular pressure in rabbits. The most active compound, carrying a succinic acid side chain, is the most soluble in aqueous buffers. Its duration of action is about 8 h and it is under evaluation as a topical antiglaucoma drug. It is hypothesized that the duration of action could be longer in compounds having both the same high water solubility and partition coefficient.
• 碳酸酐酶IX靶向放射性诊疗药物及其制备方法
  申请人：无锡诺宇医药科技有限公司

  公开号：CN117186087A

  公开（公告）日：2023-12-08

  本发明涉及碳酸酐酶IX靶向放射性诊疗药物及其制备方法，具体地，本发明涉及一种化合物或其药学上可接受的盐、酯或溶剂化物，其结构如式(I)所示，所述化合物能用于诊断和/或治疗一种或多种表达碳酸酐酶IX的肿瘤、癌症或细胞#imgabs0#